NTLAIntellia Therapeutics, Inc.
What is the market doing?
No clear lean: nothing decisive, though a crowded short (+39% of shares).
Choppy, but holding above its 200-day average. Price is +4% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 8, 2026; selling is often routine (taxes, diversification).
A crowded short, settled Sep 15, 2026, more than a week of normal trading to cover, a crowded exit.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How NTLA is trading
Intellia Therapeutics, Inc. is −16% over the past year while the S&P 500 is +18%: 34 points behind the market.
1-year return · S&P 500 +18%
- vs 200-day average
- +4.2%
vs 200-day average · close to trend
- RSI (14)
- 58
RSI (14) · neutral
- Below its 52-week high
- 53%
Below its 52-week high
Details›
- Last close2026-10-09
- $13.08
- 1 monthS&P 500 +2.7%
- +9.6%
- 1 yearS&P 500 +18%
- −16%
- 5 yearsS&P 500 +88%
- −92%
- vs 50-day average$12.14
- +7.7%
- 52-week high
- $27.98
- 52-week low
- $8.04
- Annualised volatility
- 90%
- Insider buying, net, 6 monthsForms 3/4/5 to 2026-10-08
- −$159K
| Year | Return |
|---|---|
| 2026 (year to date) | +45% |
| 2025 | −23% |
| 2024 | −62% |
| 2023 | −13% |
| 2022 | −70% |
| 2021 | +117% |
| 2020 | +271% |
| 2019 | +7.5% |
| 2018 | −29% |
| 2017 | +47% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 10 | 5 of 10 | +4.7% |
| Feb | 10 | 7 of 10 | +6.5% |
| Mar | 10 | 2 of 10 | −6.9% |
| Apr | 10 | 5 of 10 | −2.9% |
| May | 10 | 3 of 10 | +0.64% |
| Jun | 10 | 10 of 10 | +27% |
| Jul | 11 | 6 of 11 | +1.1% |
| Aug | 11 | 6 of 11 | +3.4% |
| Sep | 11 | 2 of 11 | −1.5% |
| Oct | 11 | 3 of 11 | −8.8% |
| Nov | 10 | 6 of 10 | +7.8% |
| Dec | 10 | 3 of 10 | −8.4% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.